Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing from Exploratory Research to Clinical Trials

Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?

Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.

In Situ Multiplex Analysis of Resident Microglia and Infiltrating Macrophages in Glioblastoma

Multiplex Immunofluorescence Detection of Resident Memory T Cells in Solid Tumors

Multiple Myeloma – Efficacy and Safety of 2 Different Combination Therapies

DIRA – Assay Testing for Daratumumab Clinical Trials

Driving Excellence in Immuno-Oncology

Fact Sheet – Oncology Clinical Trials at Cerba Research

Monitoring Multiple Myeloma Patients Treated With Daratumumab: Teasing Out Monoclonal Antibody Interference

Assessing Clinical Response in Multiple Myeloma Patients Treated with Monoclonal Antibodies

Immune Cell Checkpoint Profiling of Solid Tumors